Skip to Content Facebook Feature Image

A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia

Business

A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia
Business

Business

A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia

2025-04-25 08:00 Last Updated At:08:15

PETALING JAYA, Malaysia, April 25, 2025 /PRNewswire/ -- In a landmark move to safeguard the vision of Malaysia's future generation, VISTA Eye Specialist ('VISTA'), the nation's trusted eye care brand, announced a strategic collaboration Memorandum of Understanding (MoU) with EssilorLuxottica, the global leader in Medtech for vision care.

This partnership heralds a nationwide initiative to tackle the silent epidemic of childhood myopia, combining clinical excellence, global innovation, and a deep commitment to community health.

Myopia: More Than Just Blurry Vision

Myopia (short-sightedness) is emerging as a significant public health concern. Left unmanaged, it doesn't just require glasses with higher prescriptions. It opens the door to a lifetime of serious vision-threatening complications[1&2], therefore myopia management from an early age is critical[3].

"The world sees myopia as a childhood inconvenience. But unchecked, it becomes a lifetime disability," said Lim Boon Siong, Director of VISTA Eye Specialist. "Our children deserve better—and we're stepping up."

The Hidden Dangers of High Myopia[1]:

  • Retinal Detachment – Eye elongation can stretch and thin the retina, leading to tears or detachment that may cause sudden, irreversible blindness.
  • Myopic Macular Degeneration (MMD) – A leading cause of permanent central vision loss, especially in adults who were highly myopic as children.
  • Glaucoma – Myopic eyes are more vulnerable to this "silent thief of sight", which causes progressive, irreversible damage to the optic nerve.
  • Early Cataracts – High myopia increases the risk of early-onset cataracts, which often require surgery earlier in life.

By 2050, it's projected that 1 in 2 people globally will be myopic[2]. In parts of Asia, including Malaysia, up to 80–90% of schoolchildren already show signs of myopia. The time to act is now.

VISTA & EssilorLuxottica: A United Vision

Through this MoU, VISTA and EssilorLuxottica commit to an ambitious, multi-pronged strategy:

EssilorLuxottica Malaysia will:

  • Lead nationwide myopia management educational and awareness campaigns—including webinars, digital content, and parent workshops—to empower families with crucial knowledge about myopia prevention myopia management and control.

VISTA Eye Specialist will:

  • Deliver comprehensive myopia screenings through its extensive network of centers
  • Establish a referral program to connect diagnosed children with tailored myopia management solutions
  • Launch a CSR campaign starting with a free eye clinic for 200 underprivileged children, supported by volunteers from the OneSight EssilorLuxottica Foundation
  • Expand outreach to include adults and seniors, fostering lifelong eye health for all

"This is about safeguarding vision and reduce the risk of severe eye conditions linked to high myopia," said Denis Chng, Country Manager of EssilorLuxottica Malaysia. "We have to act now—healthy eyes today ensure clear sight for a lifetime!"

Looking Ahead: Hope in Sight

This collaboration marks just the beginning. Both organizations aim to scale this initiative across Malaysia—from cities to underserved rural communities. Their shared goal is to drastically reduce the incidence and impact of myopia by prioritizing early intervention, education on myopia management, and access to vision care.

About VISTA Eye Specialist

Established in 1999, VISTA Eye Specialist is Malaysia's most trusted name in eye care. VISTA was recently honored with Newsweek's Asia's Top Private Hospital Awards 2025, recognizing its dedication to clinical excellence, innovation, and patient satisfaction. With a strong presence across the country and more than 460,000 satisfied patients, VISTA is renowned for its excellence in LASIK, cataract, and myopia control services. VISTA's commitment goes beyond treatment—it is about transforming lives through vision.

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, in 2023 the Company generated consolidated revenue of Euro 25.4 billion. Its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is home to the most advanced lens technologies including Varilux, Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company's OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities. 

Reference

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia

A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles